AON
60
2
CHRW
67
3
AIG
47
6
XOM
51
3
AA
38
-2
MA
67
-5
FLR
48
3
MU
32
-6
DRI
56
2
NWSA
71
-2
ADI
45
-5
T
48
3
GOOG
69
-10
PSA
58
5
DVA
72
-3
VLO
42
2
EXR
59
4
GOOGL
59
-8
HSY
43
3
CVX
38
6
AON
60
2
CHRW
67
3
AIG
47
6
XOM
51
3
AA
38
-2
MA
67
-5
FLR
48
3
MU
32
-6
DRI
56
2
NWSA
71
-2
ADI
45
-5
T
48
3
GOOG
69
-10
PSA
58
5
DVA
72
-3
VLO
42
2
EXR
59
4
GOOGL
59
-8
HSY
43
3
CVX
38
6
Financhill
Back

Denali Therapeutics Quote, Financials, Valuation and Earnings

Buy these stocks BEFORE President Trump returns to the Oval Office

See details on which stocks are poised to surge.
Buy
60

DNLI
Denali Therapeutics

Last Price:
28.41
Seasonality Move:
6.34%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump wins! Dow to 75,000? Details here

See the explosive "Document 20" details here.

Denali Therapeutics Price Quote

$28.41
-1.23 (-4.15%)
(Updated: November 14, 2024 at 5:10 PM ET)

Denali Therapeutics Key Stats

Buy
60
Denali Therapeutics (DNLI) is a Buy
Day range:
$29.26 - $30.88
52-week range:
$14.56 - $33.33
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
13.73
P/B ratio:
3.26%
Volume:
1.6M
Avg. volume:
722.6K
1-year change:
82.96%
Market cap:
$4.3B
Revenue:
$330.5M
EPS:
$-2.76

How Much Does Denali Therapeutics Make?

Data Unavailable

Is Denali Therapeutics Growing As A Company?

Data Unavailable

Denali Therapeutics Stock Price Performance

What Is Denali Therapeutics 52-Week High & Low?

Denali Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Denali Therapeutics?

Is Denali Therapeutics Cash Flow Positive?

  • What Is DNLI Cash Flow From Operations?
    Cash flow from operations (TTM) is -$362.6M
  • What Is Denali Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $493.2M
  • What Is Denali Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$187.9M

Denali Therapeutics Return On Invested Capital

Data Unavailable

Denali Therapeutics Earnings Date & Stock Price

Denali Therapeutics Competitors

  • Who Are Denali Therapeutics's Competitors?
    Below is a list of companies who compete with Denali Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Protalix BioTherapeutics Inc (PLX)

Denali Therapeutics Dividend Yield

Denali Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0.3%
Revenue: 0% -100%

Analyst Recommendations

Buy Recommendations: 10
Hold Recommendations: 3
Sell Recommendations: 0
Price Target: 41.69
Upside from Last Price: 40.66%

Major Shareholders

  • How many DNLI shares are owned by institutional investors?
    243.1M DNLI shares are owned by institutional investors
  • How many DNLI shares are owned by insiders?
    2.7M DNLI shares are owned by insiders